Similar findings were observed in mouse melanoma models, where in vivo IL-9 blockade promoted melanoma progression, while on the other hand recombinant IL-9 enhanced the cytotoxic ability of murine melanoma-specific CD8+ T cells (132). The gene discussed is IL9; the disease is melanoma.